Premium
Intravenous midazolam as a sedative for colonoscopy: a randomized, double‐blind clinical trial
Author(s) -
YUNO K.,
IISHI H.,
TATSUTA M.,
HIFUMI K.,
OMORI M.
Publication year - 1996
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1996.76243000.x
Subject(s) - midazolam , medicine , colonoscopy , sedative , anesthesia , endoscopy , blood pressure , saline , randomized controlled trial , sedation , surgery , colorectal cancer , cancer
Methods : Forty patients, aged between 36 and 60 years, scheduled to undergo colonoscopic removal of colorectal polyps were randomly assigned to receive 0.9% saline solution ( n =20) or 0.05 mg/kg body weight of midazolam ( n =20) intravenously. Results : Midazolam significantly ( P <0.001) increased the tolerance of patients to colonoscopy. It had no significant effect on pulse or systolic blood pressure during endoscopy. Arterial oxygen saturation decreased significantly ( P <0.01) during endoscopy in patients pre‐treated with midazolam, but it did not decrease by more than 5%. Conclusions : Intravenous midazolam is useful as a sedative for colonoscopy, but we recommend continuous oxygen saturation monitoring during endoscopy.